Pathos AI Licenses JSKN016 From Alphamab for $125 Million Upfront
Pathos AI licensed ex-China rights to Alphamab Oncology’s clinical-stage TROP2/HER3 bispecific antibody-drug conjugate JSKN016 for $125 million upfront, up to $2.093 billion in milestones and high-single-digit to low-double-digit royalties. Alphamab also received a warrant…
